Piotr Korbal

75 Ujejskiego St, 
Bydgoszcz, KP, PL 
Clinical Trials:Currently Recruiting for 1 Trial
75 Ujejskiego St, 
Bydgoszcz, KP, PL 

Overview

Piotr Korbal practices practicing medicine in Bydgoszcz, Poland.

His clinical expertise encompasses Infant Respiratory Distress Syndrome, Acute Respiratory Distress Syndrome (ARDS), Tetanus, and Strep Throat.

He is actively involved in clinical research, co-authoring 15 peer reviewed articles and participating in 5 clinical trials.

Gender

Male

Locations

75 Ujejskiego St, Bydgoszcz, KP 85168, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection
An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection
Enrollment Status: Recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drug: Zanamivir
Study Phase: Phase 2
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
A Phase I/II, Randomised, Controlled Study to Assess the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Adults (Phase I) and to Healthy Adolescents and Adults (Phase II)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Combination product, Biological
Study Phase: Phase 1/Phase 2
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants
A Phase II, Randomized, Partially Blinded Study to Assess the Safety, Tolerability and Immunogenicity of Meningococcal Combined ABCWY Vaccine When Administered to Healthy Infants
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Combination product
Study Phase: Phase 2
A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome
A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome
Enrollment Status: Completed
Publish Date: April 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA
Enrollment Status: Terminated
Publish Date: July 23, 2019
Intervention Type: Combination product, Device
Study Phase: Phase 2
View 4 Less Clinical Trials

15 Total Publications

A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
A phase 3, randomized study to evaluate the safety, tolerability, and immunogenicity of V116 in children and adolescents with increased risk of pneumococcal disease (STRIDE-13).
Journal: Human vaccines & immunotherapeutics
Published: June 23, 2026

Frequently Asked Questions about Piotr Korbal

Is Piotr Korbal a top-rated expert for Infant Respiratory Distress Syndrome?

MediFind is an objective health platform that identifies experts based on real-world data. Piotr Korbal is classified as an Experienced expert for Infant Respiratory Distress Syndrome, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Piotr Korbal participate in research or clinical trials?

Yes. Piotr Korbal has published 15 articles and abstracts on conditions like Infant Respiratory Distress Syndrome. You can view a list of Piotr Korbal's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Korbal's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile